Actimab-A is a monoclonal antibody conjugated commercialized by Actinium Pharmaceuticals, with a leading Phase II program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Actimab-A’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Actimab-A is expected to reach an annual total of $17 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Actimab-A Overview
Actimab-A (HuM195-Ac-225) is under development for the treatment of patients with newly diagnosed acute myeloid leukemia (AML), relapsed/refractory acute myeloid leukemia. It consists of the lintuzumab monoclonal antibody and actinium-225. The drug candidate is administered as intravenous infusion. It is an anti-CD33 mAb (HuM195) conjugated with actinium-225. Actimab-A is based on Alpha Particle Immunotherapy Technology (APIT) platform. It was also under development for treatment of refractory (or) relapsed acute myeloid leukemia (AML) as a third line therapy and myelodysplastic syndrome.
Actinium Pharmaceuticals Overview
Actinium Pharmaceuticals (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company’s pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE Technology Platform. It develops products to treat colon, prostrate and brain cancer. ATNM is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$25 million in FY2021, compared to an operating loss of US$22.4 million in FY2020. The net loss of the company was US$24.8 million in FY2021, compared to a net loss of US$22.2 million in FY2020.
For a complete picture of Actimab-A’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Source link
#current #valuation #Actinium #Pharmaceuticalss #ActimabA
